


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:



Date: 4/19/05

By: *[Signature]*

Rena lov

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:
BALENDIRAN, GANESARATNAM K.

APPLICATION NO.: 10/826,679

FILED: APRIL 16, 2004

FOR: **OXIDOREDUCTASE INHIBITORS AND
METHODS OF SCREENING AND USING
THEREOF**

ART UNIT: 1614

CONF. NO: 9599

**Information Disclosure Statement Within Three Months of
Application Filing or Before First Action – 37 C.F.R. § 1.97(b)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 C.F.R. § 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

☒ Copies of the following references are enclosed:

- ☒ All cited references
- ☐ References marked by asterisks
- ☐ The following:

- ☐ Copies of the following references can be found in parent U.S. Application No. :
 - ☐ All cited references
 - ☐ References marked by asterisks
 - ☐ The following:
- ☐ This application was filed after 30 June 2003 and no copies of U.S. patents nor published applications are enclosed (See Notice of Deputy Commissioner Kunin on 11 July 2003).
- ☐ The following references are not in English. For each such reference, the undersigned has enclosed (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference, (iii) a copy of a reference which appears to be an English-language counterpart, or (iv) an English-language abstract for the reference prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.
 - ☐ All cited references
 - ☐ References marked by ampersands
 - ☐ The following:

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h)).

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

- ☐ Applicant further submits that no fee is due in light of the following certification under 37 C.F.R. § 1.97(e) (check only one):
 - ☐ In accordance with 37 C.F.R. § 1.97(e)(1), the undersigned hereby states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or

- ☐ In accordance with 37 C.F.R. § 1.97(e)(2), the undersigned hereby states that no item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of this statement.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2586.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).


Respectfully submitted,
Perkins Coie LLP

Date: 4-18-05


James J. Zhu
Registration No. 52,396

Correspondence Address:

Customer No. 34055
Perkins Coie LLP
Patent – LA
P.O. Box 1208
Seattle, WA 98111-1208
Phone: (310) 788-9900
Fax: (310) 788-3399

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**Form PTO-1449 (Modified)
Use several sheets if necessary)**COMPLETE IF KNOWN**

Application Number	10/826,679
Confirmation Number	9599
Filing Date	April 16, 2004
First Named Inventor	Ganesaratnam K. Balendiran
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket No.	54435.8003.US01

Sheet 1 of 14

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	A1	Ahmed, N. K., Felsted, R. L. and Bachur, N. R. Daunorubicin reduction mediated by aldehyde and ketone reductases. <i>Xenobiotica</i> 11(2):131-136 (1981).	
	A2	Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. <i>N Engl J Med</i> 341:556-62 (1999).	
	A3	Ames, B. N. Micronutrient deficiencies: A major cause of DNA damage. <i>Ann. N. Y. Acad. Sci.</i> 889:87-106 (1999).	
	A4	Arrick, B. A. and Nathan, C. F. Glutathione metabolism as a determinant of therapeutic efficacy: A review. <i>Cancer Res.</i> 44:4224-4232 (1984).	
	A5	Bailey, H. H., Gipp, J. J., Ripple, M., Wilding, G. and Mulcahy, R.T. Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. <i>Cancer Res.</i> 52:5115-8 (1992).	
	A6	Balendiran, G. K., Molina, J. A., Xu, Y., Torres-Martinez, J., Stevenes, R., Focia, P. J., Eakin, A. E., Sacchettini, J. C and Craig III, S. P. Ternary complex structure of human HGPRTase, PRPP, Mg ²⁺ , and the inhibitor HPP reveals the involvement of the flexible loop in substrate binding. <i>Protein Science</i> , 8:1023-1031 (1999).	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	2	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A7	Balendiran, G. K., Schnutgen, F., Scapin, G., Borchers, T., Xhong, N., Godbout, R., Spener, F. and Sacchettini, J. C. Crystal Structure and thermodynamic analysis of human brain fatty acid binding protein. <i>J. Biol. Chem.</i> 275(35):27045-27054 (2000).		
	A8	Balendiran, G. K., Solieim, J. C., Young, A. C. M., Hansen, T. H., Nathanson, S. G. and Sacchettini, J. C. The three-dimensional structure of an H-2L ^d -peptide complex explains the unique interaction of L ^d with beta-2 microglobulin and peptide. <i>Proc. Natl. Acad. Sci. USA</i> 94:6880-6885 (1997).		
	A9	Bando T, Fujimura M, Kasahara K, Shibata K, Shirasaki H, Heki U, Iwasa K, Ueda A, Tomikawa S, Matsuda T. Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines. <i>Anticancer Res.</i> 17:3345-3348 (1997).		
	A10	Barciszewski, J., Siboska, G. E., Pedersen, B. O., Clark, B. F. and Rattan, S. I. Furfural, a precursor of the cytokinin hormone kinetin, and base propenals are formed by hydroxyl radical damage of DNA. <i>Biochem. Biophys. Res. Commun.</i> 238:317-319 (1997).		
	A11	Beckman, K. B and Ames, B. N. Oxidative decay of DNA. <i>J. Biol. Chem.</i> 272(32):19633-19636 (1997).		
	A12	Bohren, K. M., Grimshaw, C. E., Lai, C. J., Harrison, D. H., Ringe, D., Petsko, G. A. and Gabbay, K. H. Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. <i>Biochemistry</i> 33:2021-2032 (1994).		
	A13	Borhani, D. W., Harter, T. M. and Petrash, J. M. The crystal structure of the aldose reductase. NADPH binary complex. <i>J. Biol. Chem.</i> 267(34):24841-47 (1992).		
	A14	Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. <i>Nature</i> 414:813-820 (2001).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	3	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A15	Calderone, V., Chevrier, B., Van Zandt, M., Lamour, V., Howard, E., Poterzman, A., Barth, P., Mitschler, A., Lu, J., Dvornik, D. M., Klebe, G., Kraemer, O., Moorman, A. R., Moras, D. and Podjarny, A.: The Structure of Human Aldose Reductase Bound to the Inhibitor Idd384. <i>Acta Cryst. Sect. D</i> 56:536-40 (2000).		
	A16	Cao, D., Fan, S. T. and Chung, S. S. Identification and characterization of a novel human aldose reductase-like gene. <i>J. Biol. Chem.</i> 273:11429-11435 (1998).		
	A17	Casadevall, M., da Cruz, F. P. and Kortenkamp, A. Chromium(VI)-mediated DNA damage: oxidative pathways resulting in the formation of DNA breaks and abasic sites. <i>Chemico-Biological Interactions</i> 123:117-132 (1999).		
	A18	Chaudhry, M. A. and Weinfeld, M. Reactivity of human apurinic/aprimidinic endonuclease and <i>Escherichia coli</i> exonuclease III with bistranded abasic sites in DNA. <i>J. Biol. Chem.</i> 272:15650-15655 (1997).		
	A19	Colell, A., Garcia-Ruiz, C., Miranda, M., Ardite, E., Mari, M., Morales, A., Corrales, F., Kaplowitz, N. and Fernandez-Checa, J. C. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. <i>Gastroenterology</i> 115:1541-51 (1998).		
	A20	Cramer III, R. D., Patterson, D. E. and Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). Effect of shapes on binding of steroids to carrier proteins. <i>J. Amer. Chem. Soc.</i> 110:5959-5967 (1988).		
	A21	Curtis EB, Krech R, Walsh TD. Common symptoms in patients with advanced cancer. <i>J. Palliation Care</i> 7(2):25-29 (1991).		
	A22	Dahm-Daphi, J., Sass, C. and Alberti, W. Comparison of biological effects of DNA damage induced by ionizing radiation and hydrogen peroxide in CHO cells. <i>Int. J. Radiat. Biol.</i> 76:67-75 (2000).		
	A23	Dedon, P. C. and Goldberg, I. H. Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. <i>Chem. Res. Toxicol.</i> 5:311-332 (1992).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	4	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A24	Dixit, B. L., Balendrian, G. K., Watowich, S. J., Srivastava, S., Ramana, K. V., Petrash, J. M., Bhatnagar, A. and Srivastava, S. K. Kinetic and structural characterization of the glutathione binding site of aldose reductase. <i>J. Biol. Chem.</i> 275:21587-21595 (2000).		
	A25	Estrela, J. M., Hernandez, R., Terradez, P., Asensi, M., Puertes, I. R. and Viña, J. Regulation of glutathione metabolism in Ehrlich ascites tumour cells. <i>Biochem. J.</i> 286:257-262 (1992).		
	A26	Estrela, J. M., Obrador, E., Navarro, J., Lasso De la Vega, M. C. and Pellicer, J. A. Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. <i>Nat. Med.</i> 1:84-88 (1995).		
	A27	Ferretti A, D'Ascenzo S, Knijn A, Iorio E, Dolo V, Pavan A, Podo F. Detection of polyol accumulation in a new ovarian carcinoma cell line, CABA I: a(1)H NMR study. <i>Br. J. Cancer</i> 86:1180-87 (2002).		
	A28	Gabbay, K. H. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. <i>Annu. Rev. Med.</i> 26:521-36 (1975).		
	A29	Gabbay, K. H. The sorbitol pathway and the complications of diabetes. <i>N Engl J Med</i> 288:831-36 (1973).		
	A30	Garcia-Perez, A., Martin, B., Murphy, H. R., Uchida, S., Murer, H., Cowley, B. D. Jr, Handler, J. S. and Burg, M. B. Molecular cloning of cDNA coding for kidney aldose reductase. Regulation of specific mRNA accumulation by NaCl-mediated osmotic stress. <i>J. Biol. Chem.</i> 264:16815-21 (1989).		
	A31	Glaves D. Correlation between circulation cancer cells and incidence of metastases. <i>Br. J. Cancer</i> 48:665-673 (1983).		
	A32	Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C. and Anderson, M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. <i>Proc. Natl. Acad. Sci. USA</i> 89:3070-74 (1992).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	5	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A33	Goldblatt SA, Nadel EM. Cancer cells in the circulating blood: A critical review. <i>Acta Cytol.</i> 305:6-20 (1965).		
	A34	Goodsell, D. S., Morris, G. M. and Olson, A. J. Automated docking of flexible ligands: Applications of AutoDock. <i>J. Mol. Recognit.</i> 9:1-5 (1996).		
	A35	Harrison, D. H., Bohren, K. M., Petsko, G. A., Ringe, D. and Gabbay, K. H. The Alrestatin double-decker: Binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant. <i>Biochemistry</i> 36:16134-40 (1997).		
	A36	Harrison, D. H., Bohren, K. M., Ringe, D., Petsko, G. A. and Gabbay, K. H.: An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate. <i>Biochemistry</i> 33:2011-20 (1994).		
	A37	He, Q., Khanna, P., Srivastava, S., van Kuijk, F. J. G. M. and Ansari, N. H. Reduction of 4-Hydroxynonenal and 4-hydroxy hexenal by retinal aldose reductase. <i>Biochem. Biophys. Res. Commun.</i> 247:719-722 (1998).		
	A38	Hedberg, J.J., Grafstrom, R. C., Vondracek, M., Sarang, Z., Warngard, L. and Hoog, J. O. Micro-array chip analysis of carbonyl-metabolising enzymes in normal, immortalised and malignant human oral keratinocytes. <i>Cell. Mol. Life Sci.</i> 58:1719-26 (2001).		
	A39	Hornell, T., Wormstall, E. M., Russell, J., Balendiran, G. K., Connolly, J. M., Cook, J. R. and Hansen, T. H. Alloreactive and Syngeneic CTL are Comparably Dependent on Interaction with MHC Class I α -Helical Residues. <i>J. Immunol.</i> 163:3217-3225 (1999).		
	A40	Horvath, J. J., Witmer, C. M. and Witz, G. Nephrotoxicity of the 1:1 acrolein-glutathione adduct in the rat. <i>Toxicol. Appl. Pharmacol.</i> 117:200-207 (1992).		
	A41	Jancarik, J. and Kim, S.-H. Sparse matrix sampling: A screening method for crystallization of proteins. <i>J. Appl. Cryst.</i> 24:409-411 (1991).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	6	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	.T	
	A42	Jeng KS, Chen BF, Lin HJ. En bloc resection for extensive hepatocellular carcinoma: Is it advisable? <i>World J. Surg.</i> 18:834-839 (1994).		
	A43	Jez, J. M., Schlegel, B. P and Penning, T. M. Characterization of the substrate binding site in rat liver 3alpha-hydroxysteroid/dihydrodiol dehydrogenase. The roles of tryptophans in ligand binding and protein fluorescence. <i>J. Biol. Chem.</i> 271:30190-98 (1996).		
	A44	Johnson, F., Pillai, K. M. R., Grollman, A. P., Tseng, L. and Takeshita, M. Synthesis and biological activity of a new class of cytotoxic agents: N-(3-oxopro-1-enyl)-substituted pyrimidines and purines. <i>J. Med. Chem.</i> 27:954-958 (1984).		
	A45	Kalman, T. I., Marinelli, E. R., Xu, B., Venugopala, R., Johnson, F. and Grollman, A. P. Inhibition of cellular thymidylate synthesis by cytotoxic propenal derivatives of pyrimidine bases and deoxynucleosides. <i>Biochem. Pharmacol.</i> 42:431-437 (1991).		
	A46	Kao, Y. L., Donaghue, K., Chan, A., Knight, J. and Silink, M. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. <i>Diabetes</i> 48:1338-1340 (1999).		
	A47	Kawamura I, Lacey E, Inami M, Nishigaki F, Naoe Y, Tsujimoto S, Manda T, Goto T. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI. <i>Anticancer Res.</i> 19:4091-97 (1999).		
	A48	Kawamura I, Lacey E, Yamamoto N, Sakai F, Takeshita S, Inami M, Nishigaki F, Naoe Y, Tsujimoto S, Manda T, Shimomura K, Goto T., Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by Colon26 adenocarcinoma in mice. <i>Anticancer Res.</i> 19:4105-11 (1999).		
	A49	Kawamura I, Yamamoto N, Sakai F, Yamazaki H, Goto T. Effect of Lipoprotein Lipase Activators Benzafibrate and NO-1886, on B16 Melanoma-Induced Cachexia in Mice. <i>Anticancer Res.</i> 19:4099-103 (1999).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	7	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A50	Kawamura I, Yamamoto N, Sakai F, Yamazaki H, Naoe Y, Inami M, Manda T, Shimomura K. Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor. <i>Anticancer Res.</i> 19:341-8 (1999).		
	A51	Kern KA, Norton JA. Cancer cachexia. <i>J. Parenteral and Enteral Nutr.</i> 12(3):286-98 (1988).		
	A52	Lai EC, Ng IO, Ng MM, Lok AS, Tam PC, Fan ST, Choi TK, Wong J. Long term results of resection for large hepatocellular carcinoma: A multivariate analysis of clinicopathological features. <i>Hepatology</i> 11:815-818 (1990).		
	A53	Lamour, V., Barth, P., Rogniaux, H., Poterszman, A., Howard, E., Mitschler, A., Van Dorsselaer, A., Podjarny, A. and Moras, D. Production of crystals of human aldose reductase with very high resolution diffraction. <i>Acta Cryst.</i> D55:721-23 (1999).		
	A54	Lee CS, Hwang LY, Beasely RP, Hsu HC, Lee HS, Lin TY. Prognostic significance of histologic findings in resected small hepatocellular carcinoma. <i>Acta Chir. Scand.</i> 154:199-203 (1988).		
	A55	Lee, H. Inhibitory Activity of Cinnamomum cassia Bark-Derived Component against Rat Lens aldose Reductase. <i>J. Pharm. Pharmaceut. Sci.</i> 5(3):226-30 (2002).		
	A56	Lemmen, C., Lengauer, T. and Klebe, G. FLEXS: A method for fast flexible ligand superposition. <i>J. Med. Chem.</i> 41:4502-20 (1998).		
	A57	Li, Y., Carter, D. E. and Mash, E. A. Synthesis and structure of the glutathione conjugate of chloroacetaldehyde. <i>Synthetic Communications</i> 32(10):1579-1583 (2002).		
	A58	Meister, A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. <i>Pharmac. Ther.</i> 51:155-94 (1991).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	8	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A59	Meister, A. Selective modification of glutathione metabolism. <i>Science</i> 220:472-7 (1983).		
	A60	Mitchell, J. B. and Russo, A. The role of glutathione in radiation and drug induced cytotoxicity. <i>Br. J. Cancer</i> 55, Suppl. VIII:96-104 (1987).		
	A61	Mitchell, J. B., Cook, J. A., DeGraff, W., Glatstein, E. and Russo, A. Glutathione modulation in cancer treatment: will it work? <i>Int. J. Radiation Oncology Biol. Phys.</i> 16:1289-95 (1989).		
	A62	Moriyama, T., Garcia-Perez, A. and Burg, M. B. Osmotic regulation of aldose reductase protein synthesis in renal medullary cells. <i>J. Biol. Chem.</i> 264(28):16810-14 (1989).		
	A63	Mulder, T. P., Manni, J. J., Roelofs, H. M., Peters, W. H., Wiersma, A. Glutathione S-transferases and glutathione in human head and neck cancer. <i>Carcinogenesis</i> 16(3):619-24 (1995).		
	A64	Murugesan, N., Xu, C., Ehrenfeld, G. M., Sugiyama, H., Kilkuskie, R. E., Rodriguez, L. O., Chang, L. H. and Hecht, S. M. Analysis of products formed during bleomycin-mediated DNA degradation. <i>Biochemistry</i> 24:5735-44 (1985).		
	A65	Mylari et al., A Highly Specific Aldose Reductase Inhibitor, Ethyl 1-Benzyl-3-hydroxy-2(5H)-exopyrrole-4-carboxylate, and Its Congeners. <i>J. Med. Chem.</i> 34:1011-18 (1991).		
	A66	Nath, R. G. and Chung, F. L. Detection of exocyclic 1,N2-propanodeoxyguanosine adducts as common DNA lesions in rodents and humans. <i>Proc. Natl. Acad. Sci. USA</i> 91:7491-95 (1994).		
	A67	Navaza, J. AMoRe: An automated package for molecular replacement. <i>Acta Cryst.</i> A50:157-163 (1994).		
	A68	Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. <i>Nature</i> 404:787-90 (2000).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	9	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A69	Nishimura C, Matsuura Y; Kokai Y, Akera T, Carper D, Morjana N, Lyons C, Flynn TG. Cloning and expression of human aldose reductase. <i>J. Biol. Chem.</i> 265(17):9788-92 (1990).		
	A70	Oka, M., Matsumoto, Y., Sugiyama, S., Tsuruta, N. and Matsushima, M. A Potent Aldose Reductase Inhibitor (2S,4S)-6-Fluoro-2'5'-Dioxospiro[Chroman-4,4'-Imidazolidine]-2-Carboxamide(Fidarestat): Its Absolute Configuration and Interactions with the Aldose Reductase by X-Ray Crystallography. <i>J. Med. Chem.</i> 43:2479-83 (2000).		
	A71	Penning, T. M. Molecular determinants of steroid recognition and catalysis in aldo-keto reductases. Lessons from 3alpha-hydroxysteroid dehydrogenase. <i>J. Steroid Biochem. Mol. Biol.</i> 69:211-25 (1999).		
	A72	Petrash, J. M., Murthy, B. S., Young, M., Morris, K., Rikimaru, L., Griest, T. A. and Harter, T. Functional genomic studies of aldo-keto reductases. <i>Chemico-Biological Interactions</i> 130-132:673-683 (2001).		
	A73	Pfeifer, M. A., Schumer, M. P. and Gelber, D. A. Aldose reductase inhibitors: the end of an era or the need for different trial designs? <i>Diabetes</i> 46 Suppl. 2:S82-89 (1997).		
	A74	Pfeiffer, P. The mutagenic potential of DNA double-strand break repair. <i>Toxicology Letters</i> , 96/97:119-129 (1998).		
	A75	Poulsen, H. E., Prieme, H. and Loft, S. Role of oxidative DNA damage in cancer initiation and promotion. <i>Eur. J. Cancer Prev.</i> 7:9-16 (1998).		
	A76	Povirk, L. F. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. <i>Mutation Res.</i> 355:71-89 (1996).		
	A77	Ramana, K. V., Chandra, D., Srivastava, S., Bhatnagar, A., Aggarwal, B.B. and Srivastava, S. K. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. <i>J. Biol. Chem.</i> 277(35):32063-70 (2002).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	10	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A78	Ramana, K. V., Dixit, B. L., Srivastava, S., Balendiran, G. K., Srivastava, S. K. and Bhatnagar, A. Selective recognition of glutathiolated aldehydes by aldose reductase. <i>Biochemistry</i> 39:12172-12180 (2000).		
	A79	Ramana, K. V., Dixit, B.L., Srivastava, S., Bhatnagar, A., Balendiran, G. K., Watowich, S. J., Petrash, J. M. and Srivastava, S. K. Characterization of the glutathione binding site of aldose reductase. <i>Chemico- Biological Interactions</i> 130-132:537-548 (2001).		
	A80	Raper SR. Answering questions on a microscopic scale: the detection of circulation cancer cells. <i>Surgery</i> 126:827-828 (1999).		
	A81	Rashid, R., Langfinger, D., Wagner, R., Schuchmann, H. P. and von Sonntag, C. Bleomycin versus OH-radical-induced malonaldehydic-product formation in DNA. <i>Int. J. Radiat. Biol.</i> 75(1):101-109 (1999).		
	A82	Ribrag, V., Massaad, L., Janot, F., Morizet, J., Gouyette, A. and Chabot, G. G. Main drug-metabolizing enzyme systems in human non-Hodgkin's lymphomas sensitive or resistant to chemotherapy. <i>Leukemia and Lymphoma</i> 18:303-10 (1995).		
	A83	Richter, C., Park, J. W. and Ames, B. N. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. <i>Proc. Natl. Acad. Sci. USA</i> 85:6465-6467 (1988).		
	A84	Rittner, H. L., Hafner, V., Klimiuk, P. A., Szweda, L. I., Goronzy, J. J. and Weyand, C. M. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. <i>J. Clin. Invest.</i> 103:1007-13 (1999).		
	A85	Rondeau, J. M., Tete-Favier, F., Podjarny, A., Reymann, J. M., Barth, P., Biellmann, J. F. and Moras, D. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. <i>Nature</i> 355:469-472 (1992).		
	A86	Rudra, P. K. and Krokan, H. E. Acrolein cytotoxicity and glutathione depletion in n-3 fatty acid sensitive-and resistant human tumor cells. <i>Anticancer Res.</i> 19:461-69 (1999).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	11	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A87	Ruef, J., Liu, S. -Q., Bode, C., Tocchi, M., Srivastava, S., Runge, M. S. and Bhatnagar, A. Involvement of aldose reductase in vascular smooth muscle growth and lesion formation following arterial injury. <i>Arterioscler Thromb. Vasc. Biol.</i> 20:1745-1752 (2000).		
	A88	Schapira, M., Raaka, B. M., Samuels, H. H. and Abagyan, R. Rational discovery of novel nuclear hormone receptor antagonists. <i>Proc. Natl. Acad. Sci. USA</i> 97(3):1008-13 (2000).		
	A89	Scuric, Z., Stain, S. C., Anderson, W. F. and Hwang, J. J. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. <i>Hepatology</i> 27:943-950 (1998).		
	A90	Shaw, J. P. and Chou, I.-N. Elevation of intracellular glutathione content associated with mitogenic stimulation of quiescent fibroblasts. <i>J. Cell. Physiol.</i> 129:193-198 (1986).		
	A91	Sippl W. Receptor-based 3D QSAR analysis of estrogen receptor ligands--merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. <i>J. Comput.- Aided Mol. Design</i> 14:559-72 (2000).		
	A92	Smardo, F. L. Jr, Burg, M. B. and Garcia-Perez, A. Kidney aldose reductase gene transcription is osmotically regulated. <i>Am. J. Physiol.</i> 262:C776-82 (1992).		
	A93	So, S. S. and Karplus, M. Evaluation of designed ligands by a multiple screening method: application to glycogen phosphorylase inhibitors constructed with a variety of approaches. <i>J. Comput.- Aided Mol. Design</i> 15:613-47 (2001).		
	A94	Srivastava S., Chandra, A., Ansari, N. H., Srivastava, S. K. and Bhatnagar, A. Identification of cardiac oxidoreductase(s) involved in the metabolism of the lipid peroxidation derived aldehyde, 4-hydroxynonenal. <i>Biochem. J.</i> 329:469-475 (1998).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	12	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		
	A95	Srivastava S., Chandra, A., Wang, L., Seifert, W. E. Jr., Dague, B. B., Ansari, N. H., Srivasrava S. K. and Bhatnagar, A. Metabolism of lipid peroxidation product, 4-hydroxy <i>trans</i> -2-nonenal in isolated rat heart. <i>J. Biol. Chem.</i> 273(18):10893-10900 (1998).		
	A96	Srivastava, S., Chandra, A., Bhatnagar, A., Srivastava, S. K. and Ansari, N. H. Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. <i>Biochem. Biophys. Res. Commun.</i> 217(3):741-746 (1995).		
	A97	Srivastava, S., Harter, T. M., Chandra, A., Bhatnagar, A, Srivastava, S. K. and Petrash, J. M. Kinetic studies of a FR-1, a growth factor-inducible aldo-keto reductase. <i>Biochemistry</i> 37:12909-12917 (1998).		
	A98	Srivastava, S., Watowich. S., Petrash, J. M., Srivastava, S. K. and Bhatnagar, A. Structural and kinetic determinants of aldehyde reduction by aldose reductase. <i>Biochemistry</i> 38:42-54 (1999).		
	A99	Suthanthiran, M., Anderson, M. E., Sharma, V. K. and Meister, A. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. <i>Proc. Natl. Acad. Sci. USA</i> 87:3343-47 (1990).		
	A100	Takahashi M, Hoshi A, Fujii J, Miyoshi E, Kasahara T, Suzuki K, Aozasa K, Taniguchi N. Induction of Aldose Reductase Gene Expression in LEC Rats During the Development of the Hereditary Hepatitis and Hepatoma. <i>Jpn. J. Cancer Res.</i> 87:337-41 (1996).		
	A101	Takahashi, M., Fujii, J., Miyoshi, E., Hoshi, A. and Taniguchi, N. Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes. <i>Int. J. Cancer</i> 62:749-754 (1995).		
	A102	Tang B, Kruger WD, Chen G, Shen F, Lin WY, Mboup S, London WT, Evans AA. Hepatitis B Viremia is Associated with Increased Risk of Hepatocellular Carcinoma in Chronic Carriers. <i>J. Med. Virol.</i> 72:35-40 (2004).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	13	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A103	Terradez, P., Asensi, M., Lasso de la Vega, M. C., Puertes, I., Viña, J. and Estrela, J. M. Depletion of tumour glutathione in vivo by buthionine sulfoximine: modulation by the rate of cellular proliferation and inhibition of cancer growth. <i>Biochem. J.</i> 292:477-483 (1993).		
	A104	Trush, M. A. and Kensler, T. W. An overview of the relationship between oxidative stress and chemical carcinogenesis. <i>Free Radic. Biol. Med.</i> 10:201-209 (1991).		
	A105	Tsai, W. Y., Chang, W. H., Chen, C. H. and Lu, F. J. Enhancing effect of patented whey protein isolate (Immunocal) on cytotoxicity of an anticancer drug. <i>Nutrition and Cancer</i> 38(2):200-208 (2000).		
	A106	Uchida, S., Garcia-Perez, A., Murphy, H. and Burg, M. Signal for induction of aldose reductase in renal medullary cells by high external NaCl. <i>Am. J. Physiol.</i> 256:C614-20 (1989).		
	A107	Urzhumtsev, A., Tete-Favier, F., Mitschler, A., Barbanton, J., Barth, P., Urzhumtseva, L., Biellmann, J. F., Podjarny, A. and Moras, D. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. <i>Structure</i> 5:601-12 (1997).		
	A108	Vander Jagt, D. L., Kolb, N. S., Vander Jagt, T. J., Chino, J., Martinez, F. J., Hunsaker, L. A. and Royer, R. E. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. <i>Biochimica et Biophysica Acta</i> 1249:117-26 (1995).		
	A109	Wang, J., Chen, W., Tsai, S., Sung, P. and Huang, R. An in vitro model for evaluation of vaporous toxicity of trichloroethylene and tetrachloroethylene to CHO-K1 cells. <i>Chemico- Biological Interactions</i> 137:139-54 (2001).		
	A110	Wilson, D. K., Bohren, K. M., Gabbay, K. H. and Quiocho, F. A. An unlikely sugar substrate site in the 1.65 Å structure of the human aldose reductase holoenzyme implicated in diabetic complications. <i>Science</i> 257:81-84 (1992).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/826,679
				Confirmation Number	9599
				Filing Date	April 16, 2004
				First Named Inventor	Ganesaratnam K. Balendiran
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	14	of	14	Attorney Docket No.	54435.8003.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T.	
	A111	Wilson, D. K., Tarle, I., Petrash, J. M. and Quiocho, F. A. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. <i>Proc. Natl. Acad. Sci. USA</i> 90:9847-51 (1993).		
	A112	Yermilov, V., Yoshie, Y., Rubio, J. and Ohshima, H. Effects of carbon dioxide/bicarbonate on induction of DNA single-strand breaks and formation of 8-nitroguanine, 8-oxoguanine and base-propenal mediated by peroxynitrite. <i>FEBS Letters</i> 399:67-70 (1996).		
	A113	Yu, Y. Y., Myers, N. B., Hilbert, C. M. Harris, M. R., Balendiran, G. K. and Hansen, T. H. Definition and transfer of an epitope specific for peptide empty forms of MHC class I. <i>International Immunology</i> 11(12):1897-1905 (1999).		
	A114	Yu, Y. Y. L., Turnquist, H. R., Myers, N. B., Balendiran, G. K., Hansen, T. H. and Solheim, J. C. An extensive region of an MHC class I alpha2 domain loop influences interaction with the assembly complex. <i>J. Immunol.</i> 163:4427-4433 (1999).		
	A115	Zeindl-Eberhart E, Haraida S, Liebmann S, Jungblut PR, Lamer S, Mayer D, Jager G, Chung S, Rabes HM. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. <i>Hepatology</i> 39(2):540-49 (2004).		
	A116	Zeindl-Eberhart, E., Jungblut, P. R., Otto, A. and Rabes, H. M. Identification of tumor-associated protein variants during rat hepatocarcinogenesis. Aldose reductase. <i>J. Biol. Chem.</i> 269(20):14589-14594 (1994).		
	A117	Zeindl-Eberhart, E., Jungblut, P. R., Otto, A., Kerler, R. and Rabes, H. M. Further characterization of a rat hepatoma-derived aldose-reductase-like protein--organ distribution and modulation in vitro. <i>Eur. J. Biochem.</i> 247:792-800 (1997).		
	A118	Zhou XD. Recurrence and Metastasis of Hepatocellular Carcinoma: Progress and Prospects. <i>Hepatobiliary Pancreat. Dis. Int.</i> 1(1):35-41 (2002).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	